NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDA
Post# of 66
(Total Views: 293)
Posted On: 01/28/2021 3:32:08 PM
NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in First Cohort of MS1819 Study
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, announced that it has completed patient enrollment in the first cohort of its Phase 2b OPTION 2 extension study. The study is evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the announcement, the company noted that the Phase 2b OPTION 2 trial extension arm is dosing patients at sites in the United States and Europe; patients in this study previously participated in arms of the OPTION 2 trial. The ultimate objective of the MS1819 program is to offer cystic fibrosis patients a safe and effective treatment to control EPI, a debilitating gastrointestinal condition common in patients with cystic fibrosis; the condition can lead to a chronic nutritional deficiency. AZRX’s MS1819 is a recombinant lipase enzyme designed for the treatment of EPI associated with cystic fibrosis and chronic pancreatitis. “The extension arm of the Phase 2b OPTION 2 trial is providing us with an opportunity to determine both the optimized dosage and delivery mechanism of MS1819,” said AzurRx BioPharma president and CEO James Sapirstein in the press release. “We have fully enrolled the most important cohort of the extension study and would like to thank both our clinical collaborators and patients for their continued participation in the study. We continue to be encouraged by the absence of any reports of serious adverse events to date, and eagerly look forward to reporting topline results from this trial in Q1 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, announced that it has completed patient enrollment in the first cohort of its Phase 2b OPTION 2 extension study. The study is evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the announcement, the company noted that the Phase 2b OPTION 2 trial extension arm is dosing patients at sites in the United States and Europe; patients in this study previously participated in arms of the OPTION 2 trial. The ultimate objective of the MS1819 program is to offer cystic fibrosis patients a safe and effective treatment to control EPI, a debilitating gastrointestinal condition common in patients with cystic fibrosis; the condition can lead to a chronic nutritional deficiency. AZRX’s MS1819 is a recombinant lipase enzyme designed for the treatment of EPI associated with cystic fibrosis and chronic pancreatitis. “The extension arm of the Phase 2b OPTION 2 trial is providing us with an opportunity to determine both the optimized dosage and delivery mechanism of MS1819,” said AzurRx BioPharma president and CEO James Sapirstein in the press release. “We have fully enrolled the most important cohort of the extension study and would like to thank both our clinical collaborators and patients for their continued participation in the study. We continue to be encouraged by the absence of any reports of serious adverse events to date, and eagerly look forward to reporting topline results from this trial in Q1 2021.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)